Company & Sponsor Intelligence

UCB Pharma

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials24

Recruiting0

Completed23

Countries7

Therapeutic footprint

epilepsyparkinsons

Indexed studies

NCT00139867A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease
parkinsons · United StatesPHASE3

NCT01210690Observational Study in Infants Who Are Prescribed Treatment With Keppra® (Levetiracetam) Oral Solution
epilepsy · FranceCOMPLETED

NCT00535392Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy
epilepsy · United StatesPHASE2

NCT00630357Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy
epilepsy · PHASE4

NCT01504529Non-interventional, Retrospective, Multi-center Study to Evaluate Non-motor Symptoms in Advanced Parkinson Disease (PD) Patients Already Treated With Rotigotine
parkinsons · SpainCOMPLETED

NCT00630630Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy
epilepsy · PHASE4

NCT00150787Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy.
epilepsy · PHASE3

NCT01405508Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy
epilepsy · United StatesPHASE3

NCT00175825A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
epilepsy · United StatesPHASE2

NCT00593606Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine
parkinsons · PHASE3

NCT00150709A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy
epilepsy · PHASE3

NCT01921205Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures
epilepsy · United StatesPHASE3

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →